ESTRELLA IMMUNOPHARMA INC (ESLA) Forecast, Price Target & Analyst Ratings

NASDAQ:ESLA • US2975841048

Current stock price

1.05 USD
0 (0%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ESTRELLA IMMUNOPHARMA INC (ESLA).

Forecast Snapshot

Consensus Price Target

Price Target
$8.16
+ 677.14% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
N/A
Period
Q3 / 2026
EPS Estimate
-$0.13
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
82.86%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$8.16
Upside
+ 677.14%
From current price of $1.05 to mean target of $8.16, Based on 7 analyst forecasts
Low
$8.08
Median
$8.16
High
$8.40

Price Target Revisions

1 Month
0.00%
3 Months
-50.00%

Price Target Summary

7 Wall Street analysts provided a forecast for the next 12 months for ESLA. The average price target is 8.16 USD. This implies a price increase of 677.14% is expected in the next year compared to the current price of 1.05.
The average price target has been revised downward by 50% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

ESLA Current Analyst RatingESLA Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0

Analyst Ratings History

ESLA Historical Analyst RatingsESLA Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -13 -12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 0 2 4 6

Analyst Ratings Consensus

ChartMill Buy Consensus
82.86%
ESLA was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about ESLA.
In the previous month the buy percentage consensus was at a similar level.
ESLA was analyzed by 7 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-02-09D. Boral CapitalMaintains Buy -> Buy
2026-01-28D. Boral CapitalMaintains Buy -> Buy
2025-11-03D. Boral CapitalMaintains Buy -> Buy
2025-08-12D. Boral CapitalMaintains Buy -> Buy
2025-06-03D. Boral CapitalMaintains Buy -> Buy
2025-05-29D. Boral CapitalMaintains Buy -> Buy
2025-02-21D. Boral CapitalMaintains Buy -> Buy
2025-02-18D. Boral CapitalInitiate Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
N/A
Period
Q3 / 2026
EPS Estimate
-$0.13
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
-121.00%
Number of Analysts
3

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%

Next Earnings Summary

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
ESLA revenue by date.ESLA revenue by date.
N/AN/AN/AN/A
402.53%		N/A
101.09%		N/A
50.64%		N/A
34.07%		N/A
10.54%
EBITDA
YoY % growth
ESLA ebitda by date.ESLA ebitda by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
ESLA ebit by date.ESLA ebit by date.
-250K-1.685M
-574.16%		-11.114M
-559.45%		-7.31M
34.23%		-13.063M
-78.69%		N/A
-290.42%		N/A
-40.00%		N/A
63.07%		N/A
1,128.29%		N/A
138.84%		N/A
58.60%		N/A
37.29%		N/A
10.92%
Operating Margin
ESLA operating margin by date.ESLA operating margin by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EPS
YoY % growth
ESLA eps by date.ESLA eps by date.
N/AN/AN/AN/AN/AN/AN/A
-32.61%		N/A
-14.75%		N/A
67.14%		N/A
756.52%		N/A
127.15%		N/A
51.31%		N/A
29.29%		N/A
5.37%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q3 / 26 Q4 / 26
EPS
Q2Q % growth		-0.13
-121.00%		-0.12
18.40%
Revenue
Q2Q % growth
EBITDA
Q2Q % growth		N/AN/A
EBIT
Q2Q % growth		-12.852M
-167.68%		-12.138M
-1,879.45%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

ESLA Yearly Revenue VS EstimatesESLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
ESLA Yearly EPS VS EstimatesESLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 4 6

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
14.47%
EPS Next 5 Year
56.73%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

ESTRELLA IMMUNOPHARMA INC / ESLA Forecast FAQ

What is the average price target for ESTRELLA IMMUNOPHARMA INC (ESLA) stock?

7 analysts have analysed ESLA and the average price target is 8.16 USD. This implies a price increase of 677.14% is expected in the next year compared to the current price of 1.05.

Can you provide the consensus estimates for ESTRELLA IMMUNOPHARMA INC next earnings?

The consensus EPS estimate for the next earnings of ESTRELLA IMMUNOPHARMA INC (ESLA) is -0.13 USD and the consensus revenue estimate is 0 USD.

What is the consensus rating for ESLA stock?

The consensus rating for ESTRELLA IMMUNOPHARMA INC (ESLA) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.